Company Profile
Ocugen Stock Price, News & Analysis
- Ticker:
- OCGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.24 USD (-1.59%)
Close
Last updated: July 28, 2026
454M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, OCGN closed down 1.59% at $1.24. No new same-company headline was identified in the current news window.
Company overview
Business overview
Ocugen is a biotechnology company focused on ophthalmology, gene therapy, and vaccine-related programs. Its story has been shaped by a mix of platform ambition and strategic pivots.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Ocugen sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical development, partnership progress, and the ability to create value across a narrow set of programs.
Position Within the Biotechnology Landscape
Ocugen is a high-uncertainty biotech name whose valuation is driven by strategy and development milestones.
Future catalysts
Ocugen’s catalysts are the gene-therapy and biologics pipeline, with any update on retinal or vaccine-related work shaping the next leg. The market will want a clearer human-data path before assigning more value.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ocugen (OCGN)?
Ocugen (OCGN) most recently closed at 1.24 USD, a -1.59% move versus the previous session.
What is the market cap of Ocugen (OCGN)?
Ocugen currently has a market capitalization of 454M USD on BioPharmSignal.
What does Ocugen do?
Ocugen is a biotechnology company focused on ophthalmology, gene therapy, and vaccine-related programs. Its story has been shaped by a mix of platform ambition and strategic pivots.
On which exchange is OCGN stock listed?
Ocugen (OCGN) is associated with NASDAQ, United States, Biopharma.
What is Ocugen?
Ocugen’s catalysts are the gene-therapy and biologics pipeline, with any update on retinal or vaccine-related work shaping the next leg.
Which conditions is Ocugen targeting with Ocugen?
Ocugen is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Ocugen describe recent progress with Ocugen?
Ocugen’s catalysts are the gene-therapy and biologics pipeline, with any update on retinal or vaccine-related work shaping the next leg.
What future catalysts are investors watching for Ocugen?
Ocugen’s catalysts are the gene-therapy and biologics pipeline, with any update on retinal or vaccine-related work shaping the next leg. The market will want a clearer human-data path before assigning more value.